Cozen O’Connor: District Court Denies Takeda's Motion for a New Trial

District Court Denies Takeda's Motion for a New Trial

Shelby Riney, of the firm's Commercial Litigation department, authored, "District Court Denies Takeda's Motion for a New Trial," for the ABA Section of Litigation, Products Liability, News & Developments. The U.S. District Court for the Western District of Louisiana denied the Rule 59 Motion for a new trial filed by Takeda Pharmaceuticals U.S.A. and related entities (Takeda) in a case involving Takeda's anti-diabetes medication Actos and allegations that it causes bladder cancer (Actos Product Liability Litigation). Among other issues, Takeda contended that the jury's $9 billion punitive award resulted from passion and prejudice. While the court remitted the jury's $9 billion punitive award to $37 million, it defended its finding that Takeda acted in bad faith when it spoliated evidence.

To read the full article, click here.


Related Attorneys

Shelby K. Riney

Member

sriney@cozen.com

(215) 665-5521


Related Practices